Multiple Sclerosis Drugs Market to Exhibit 5.9% CAGR from 2023 to 2030; EMA and U.S. FDA Accept Ozanimod Applications for Treatment of RMS and RRMS

The global multiple sclerosis drugs market size stood at USD 22.32 billion in 2022. The market value is slated to rise from USD 21.33 billion in 2023 to USD 31.90 billion by 2030 at a CAGR of 5.9% during 2023-2030. The market expansion is driven by the rising focus on R&D initiatives for the development of innovative drugs by leading industry players. Additional factor propelling market expansion is the implementation of favorable government initiatives in various countries.

Fortune Business Insights™ presents this information in its report titled “Multiple Sclerosis Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Immunomodulators, Immunosuppressants, Interferons, and Others), By Route of Administration (Oral and Injection {Intramuscular, Subcutaneous, and Intravenous}), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2023-2030”.

Lockdown Restrictions Slowed Industry Growth amid the COVID-19 Pandemic

The COVID-19 pandemic slowed the growth of industry players in 2020. The resource reallocation for COVID-19 treatment and disruptions in supply chain additionally affected product sales. However, in 2021, clinics and hospitals recorded an increase in patient volumes and an escalated demand for the treatment of multiple sclerosis. This helped in the regularization of sales in the latter pandemic period.

EMA and U.S. FDA Accept Ozanimod Applications for Treating RMS and RRMS

In June 2019, Celgene Corporation announced that the New Drug Application for Ozanimod for treating people exhibiting RMS (Relapsing forms of multiple sclerosis) was accepted for review by the U.S. FDA. Furthermore, the European Medicines Agency (EMA) also accepted for review the Marketing Authorization Application for Ozanimod for treating adults with RRMS (relapsing-remitting multiple sclerosis) in the European Union.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386

Surge in Market Value Owing to Proactive Recommendations and Government Support

One of the pivotal factors propelling the multiple sclerosis drugs market growth is the proactive government recommendations and support across various regions. The governments of numerous countries such as the U.K. and the U.S. have provided recommendations on the deployment of these drugs.

However, market expansion could be affected by the high costs associated with the drug. The high pricing makes it inefficient to address the unmet requirements of impacted people.

Pivotal Players Ink Collaborative Deals to Strengthen Industry Expansion

Major industry players focus on the adoption of a range of strategic initiatives for the consolidation of market positions. These include partnership agreements, acquisitions, mergers, and the launch of new solutions. Additional initiatives include an upsurge in research activities and the development of new products.

Besides, some companies are participating in health conferences for strengthening their product portfolios.

Key Players Profiled:

• Biogen (U.S.)


• Pfizer Inc. (U.S.)


• F. Hoffmann-La Roche Ltd. (Switzerland)


• Novartis AG (Switzerland)


• Merck & Co., Inc. (U.S.)


• Sanofi (France)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Janssen Pharmaceuticals, Inc. (Johnson & Johnson Corporation) (New Jersey)


• Bristol-Myers Squibb Company (U.S.)

Notable Industry Development

• July 2021 – InnoCare Pharma and Biogen Inc. announced their collaboration and license for Orelabrutinib. The solution is an oral small molecule for the treatment of multiple sclerosis.

Further Report Findings

• Considering the regional landscape, the market has been analyzed across North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. The North America multiple sclerosis drugs market share is estimated to register appreciable growth over the projected period. The rise is driven by the escalating demand for molecular antibody drugs and an upsurge in R&D investments.


• The Europe market is expected to grow at a substantial pace throughout the estimated period. The upsurge is due to active government regulations and an increase in favorable reimbursement policies.


• The Asia Pacific market is anticipated to depict considerable expansion throughout the forecast period. This is on account of the enhanced distribution networks of pharmaceutical companies in the region.


• Based on drug class, the market for multiple sclerosis drugs is segmented into immunosuppressants, interferons, immunomodulators, and others. Of these, the immunomodulators segment is slated to record commendable growth over the anticipated period.


• On the basis of distribution channel, the hospital pharmacy segment is expected to register considerable expansion throughout the projected period. The surge is due to favorable government policies.

Table of Segmentation